| 1 |
Morales-Sánchez A, Fuentes-Pananá EM. Human viruses and cancer[J]. Viruses, 2014,6(10):4047-4079.
|
| 2 |
Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease[J]. Annu Rev Immunol, 2015,33:787-821.
|
| 3 |
Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections[J]. Clin Microbiol Rev, 2011,24(1):193-209.
|
| 4 |
Stanfield BA, Luftig MA. Recent advances in understanding Epstein-Barr virus[J]. F1000 Res, 2017,6:386.
|
| 5 |
Yoshida M, Watanabe T, Narita Y, et al. The Epstein-Barr virus BRRF1 gene is dispensable for viral replication in HEK293 cells and transformation[J]. Sci Rep, 2017,7(1):6044.
|
| 6 |
van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT[J]. Blood, 2001,98(4):972-978.
|
| 7 |
Robertson ES. Epstein-Barr virus[M]//Farrell PJ. Epstein-Barr virus genome. Norfolk: Caister Academic Press, 2005:263-287.
|
| 8 |
Lee WI, Lin JJ, Hsieh MY, et al. Immunologic difference between hypersensitivity to mosquito bite and hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection[J]. PLoS One, 2013,8(10):e76711.
|
| 9 |
Trempat P, Tabiasco J, Andre P, et al. Evidence for early infection of non-neoplastic natural killer cells by Epstein-Barr virus[J]. J Virol, 2002,76:11139-11142.
|
| 10 |
Brisse E, Wouters CH, Andrei G, et al. How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis[J]. Front Immunol, 2017,8:1102.
|
| 11 |
Wang J, Deng L, Huang J, et al. High expression of fibronectin 1 suppresses apoptosis through the NF-κb pathway and is associated with migration in nasopharyngeal carcinoma[J]. Am J Transl Res, 2017,9(10):4502-4511.
|
| 12 |
Grossman L, Chang C, Dai J, et al. Epstein-Barr virus induces adhesion receptor CD226 (DNAM-1) expression during primary B-cell transformation into lymphoblastoid cell lines[J]. mSphere, 2017,2(6):e00305-17.
|
| 13 |
Foltyn S, Strycharz-Dudziak M, Drop B, et al. Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer[J]. Infect Agent Cancer, 2017,12:31.
|
| 14 |
Kelesidis T, Humphries R, Terashita D, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County[J]. J Med Virol, 2012,84(5):777-785.
|
| 15 |
Chuang HC, Lay JD, Hsieh WC, et al. Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target[J]. Cancer Sci, 2007,98(9): 1281-1287.
|
| 16 |
Wirtz T, Weber T, Kracker S, et al. Mouse model for acute Epstein-Barr virus infection[J]. Proc Natl Acad Sci U S A, 2016,113(48):13821-13826.
|
| 17 |
Cheng Y, Zhu X, Zhang T, et al. EBV-HLH children with reductions in CD4+T cells and excessive activation of CD8+T cells[J]. Pediatr Res, 2017,82(6):952-957.
|
| 18 |
Sato K, Misawa N, Nie C, et al. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice[J]. Blood, 2011,117(21):5663-5673.
|